As part of the Human Cancer Model Initiative, scientists and physicians at Cold Spring Harbor Laboratory (CSHL) and Northwell Health contributed more than 150 organoid models to the  “Compendium of Next-Generation Patient-Derived Models for Diverse Cancers.” According to CSHL Cancer Center Director David Tuveson, “These organoids more closely reflect the biology of a patient’s tumor, providing researchers with powerful tools to accelerate discovery and develop more personalized treatment strategies.”

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively. This new understanding may help researchers develop new treatment approaches for these aggressive skin cancers.

Fralin Biomedical Research Institute at VTC scientists are investigating how breast milk composition changes throughout the day to match infants’ metabolic needs. Supported by a Gerber Foundation grant, the study will compare morning and evening microRNA levels and track infant growth, potentially informing pumped-milk practices, improved formula design, and policies supporting equitable breastfeeding access.

A protein secreted by common cancer types makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. The discovery could lead to new ways of monitoring and reducing lung metastasis risk in cancer patients.

A drug-free technology that uses low-intensity electric fields reduced tumor growth and spread in preclinical models of triple-negative breast cancer, one of the most aggressive forms of the disease, according to new research from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

A growing body of scientific insight is transforming how cancer treatment resistance is understood, highlighting a powerful cellular process known as lactylation as a central driver of disease progression and therapeutic failure. This emerging perspective is reshaping the landscape of oncology, pointing to new opportunities for more precise and effective interventions.

A growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape. A new review highlights how this key metabolic regulator is emerging as a critical driver of tumor development and a promising focus for future cancer therapies.